Government-Owned Inventions; Availability for Licensing, 23729-23731 [E9-11705]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices
the control of the cell cycle and
alterations in CDK expression, function,
or regulation and are associated with
diseases characterized by cellular
proliferation. Increasing CDK activity
has been reported in many cancers.
Likewise, the loss of inhibitory activity
has been observed in a wide variety of
primary human tumors and human
tumor-derived cell lines, including lung,
breast, brain, bone, skin, bladder,
kidney, ovary, liver, colon, and pancreas
as well as in leukemia. These
compounds have also been found to
potently inhibit GSK3beta activity
which has recently been linked to a
variety of cellular processes and several
disparate areas of biology. In particular,
GSK3beta activity has been strongly
implicated in Alzheimer’s as well as
cardiac failure. Thus, the compounds of
this invention offer unique
opportunities for a variety of
indications.
Applications: CDK/GSK3beta
inhibitor therapeutics for the treatment
of several indications including various
cancers, neurodegenerative diseases,
and cardiac conditions.
Development: Pre-clinical stage of
development.
Inventors: Daniel W. Zaharevitz et al.
(NCI).
Publication: DW Zaharevitz et al.
Discovery and initial characterization of
the paullones, a novel class of smallmolecule inhibitors of cyclin-dependent
kinases. Cancer Res. 1999 Jun
1;59(11):2566–2569.
Patent Status: HHS Reference No. E–
025–1998/0—
• U.S. Patent No. 6,610,684, issued
August 26, 2003;
• Australian Patent Nos. 780528 and
778735, issued March 24, 2005 and
December 16, 2004;
• Canada Patent Application No.
2335115, filed June 16, 1999;
• Japanese Patent Application No.
2000–554735, filed June 16, 1999;
• United Kingdom Patent No.
1086105, validated March 01, 2006 ((E–
025–1998/0–GB–09);
• French Patent No. 1086105,
validated March 01, 2006 (E–025–1998/
0–FR–10); and
• German Patent No. 69930120.3,
validated March 16, 2006 (E–025–1998/
0–DE–11).
Licensing Status: Available for
licensing.
Licensing Contact: Whitney A.
Hastings; 301–451–7337;
hastingw@mail.nih.gov.
VerDate Nov<24>2008
15:27 May 19, 2009
Jkt 217001
Dated: May 13, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–11706 Filed 5–19–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Antibody and Immunotoxin Treatments
for Mesothelin-Expressing Cancers
Description of Technology:
Mesothelin is a cell surface protein that
is highly expressed in aggressive
cancers such as malignant
mesothelioma, ovarian cancer and
pancreatic cancer. As a result,
mesothelin is an excellent candidate for
tumor targeted immunotherapeutics.
However, the antibodies against
mesothelin that are available for clinical
trials are of murine origin. These
antibodies have the potential to elicit
immune responses in patients, which
may adversely affect the ability to
provide patients with repeated doses.
Thus, the clinical application of the
antibodies may be limited.
In order to address the issue of
immunogenicity in patients, NIH
inventors have generated antimesothelin antibody variable fragments
(Fv) of human origin. These antibody
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
23729
fragments (HN1 and HN2) have the
ability to efficiently recognize
mesothelin on the surface of numerous
cancer cells. As a result, these antibody
fragments represent an attractive
therapeutic alternative to the murine
anti-mesothelin antibodies currently
being tested in clinical trials.
Application:
• Use as an antibody therapeutic for
mesotheliomas, pancreatic tumors and
ovarian tumors.
• Use in an immunotoxin therapeutic
for mesotheliomas, pancreatic tumors
and ovarian tumors.
• Diagnostic for the detection of
mesothelin positive tumors.
• Research agent for the detection of
mesothelin.
Advantages:
• Fully human antibody reduces
potential immunogenicity, thereby
allowing repeated dosing.
• Antibody specificity improves the
therapeutic efficacy of the agent.
Development Status: Preclinical stage
of development with some pre-clinical
data available.
Inventors: Mitchell Ho et al. (NCI).
Patent Status: U.S. Provisional
Application No. 61/162,778, filed 24
Mar 2009 (HHS Reference E–091–2009/
0–US–01)
Related Technologies/Publications:
• U.S. Patent 6,083,502 entitled
‘‘Mesothelium Antigen and Methods
and Kits For Targeting It.’’
• PCT Application PCT/US97/0224
entitled ‘‘Mesothelium Antigen and
Methods and Kits For Targeting It.’’
• U.S. Patent 6,809,184 entitled
‘‘Antibodies, Including Fv Molecules,
and Immunoconjugates Having High
Binding Affinity for Mesothelin and
Methods for Their Use.’’
• PCT Application PCT/US98/25270
entitled ‘‘Antibodies, Including Fv
Molecules, and Immunoconjugates
Having High Binding Affinity for
Mesothelin and Methods for Their Use.’’
• U.S. Patent 7,081,518 entitled
‘‘Anti-mesothelin antibodies having
high binding affinity.’’
• PCT Application PCT/US00/14829
entitled ‘‘Immunoconjugates Having
High Binding Affinity Improvement of
scFVsr Ab’s with Higher Affinity for
Mesothelin.’’
Licensing Status: Available for
licensing.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Laboratory of Molecular Biology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
E:\FR\FM\20MYN1.SGM
20MYN1
23730
Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices
develop, evaluate, or commercialize
antibody-based treatments of
mesothelin-expressing cancers. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Simple Biosensors Based on Electrical
Percolation Biological Semiconductors
Description of Technology: The
invention offered for licensing is in the
field of biosensors with application in
diagnostics and in regulation of
implantable biomedical devices. More
specifically, it is related to biological
semiconductors based on the electrical
percolation of single-walled carbon
nanotubes (SWNTs). The nanotubes are
embedded with biological ligands (e.g.,
antibodies). The electrical resistance of
a semiconducting SWNT is found to
dramatically increase upon the
actuation by a specific antigen.
Measurement of the change in resistance
correlates with the concentration of the
specific antigen and thus provides for
quantitative determination and
diagnostics of biological samples. The
simple printing fabrication of electrical
percolation biological semiconductors
(EPBSC) can facilitate assembly of
numerous types of gates (e.g.,
antibodies, DNA, etc.) and print many of
such gates on the same chip for the
creation of biological CPUs for various
biomedical applications, including
direct biodetection and regulation of
implantable biomedical devices.
Applications:
(a) Miniaturized biosensors for
various biomedical applications,
including: (i) Direct biodetection of
microbial pathogens and their toxins ii)
diagnostics and prognostics of human
diseases (e.g., cancer, cardiovascular, or
other biomarkers) (iii) detection and
analysis of nucleic acids (e.g., DNA,
RNA) (iv) detection and analysis of
other analytes (carbohydrates, fatty
acids, organic or inorganic compounds).
—Point of Care (POC) diagnostics (e.g.,
Physician’s office, home-use)
—Military applications (e.g., remote
sensing of biowarfare agents)
(b) Monitor food safety and detection
of environmental pollution.
(c) Regulation of implantable
biomedical devices such as insulin
pumps or artificial hearts.
(d) New generation of personal
detectors (e.g., food allergens,
cardiovascular event, etc.).
Advantages:
(a) The electrical percolation
biological semiconductors (EPBSC) are
relatively simple to assemble, and do
not require specialized fabrication
facilities or experience which may
broaden the use of EPBSC in a similar
VerDate Nov<24>2008
15:27 May 19, 2009
Jkt 217001
way that PDMS (Polydimethylsiloxane)
technology has broadened the use of
lab-on-a-chip.
(b) Many EPBSC can be fabricated
into the same chip enabling
simultaneous detection of many
analytes.
(c) Electronic based EPBS detection
enable simple digital signal
amplification and analysis.
(d) EPBSC can be relatively stable
with respect to retention of biological
viability and thus can be stored for a
long period of time before use.
(e) EPBSC enable device
miniaturization.
(f) EPBSC are relatively simple to use
and may not require special equipment
or a skilled operator. Thus, these
biosensors can be utilized in a Physician
Office setting, for military applications
and for possibly remote sensing for
detections of biowarfare materials.
(g) EPBSC devices will offer speed of
detection, ease of use, and it will be
inexpensive to make.
Development Status: Proof of concept
was demonstrated. For example, using
anti-Staphylococcal Enterotoxin B (SEB)
IgG antibodies as a gate, and the SEB
antigen as an actuator, the inventors
could detect as little as 0.1 ng/mL of
SEB.
Market: According to market research
reports from 2003–2004 the global
market for biosensors was projected to
grow from approximately $7.0 billion in
2004 to approximately $9.5 billion in
2009, an average annual growth of about
7.0%. Ninety-nine percent (99%) of the
biosensor’s market is dominated by
biomedical and life sciences, while only
one percent (1.0%) with applications in
environmental monitoring.
Because of the unique advantages
offered by this technology (i.e., diversity
of applications, simplicity of use and
low cost), there is a good probability
that if technically successful it will
become commercially successful and
financially rewarding.
Inventors: Avraham Rasooly (NCI) et
al.
Patent Status: U.S. Provisional
Application No. 61/115,546 filed 18
Nov 2008, entitled ‘‘Electrical
Percolation Biomedical
Semiconductors’’ (HHS Reference No.
E–040–2009/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contacts: Uri Reichman,
Ph.D., MBA; 301–435–4616;
UR7a@nih.gov; Michael Shmilovich, JD;
301–435–5019; shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Cancer
Diagnostic Program, and the Food and
Drug Administration, the Center for
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Devices and Radiological Health, Office
of Science and Engineering
Laboratories, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Electrical Percolation
Biological Semiconductors for
biodetection. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
C57BL/6J Embryonic Stem Cell Lines
Generated Using Serum-Free Media
Description of Technology: NIH
investigators have generated Embryonic
Stem (ES) cell clones from C57BL/6J
mice in a defined medium. These cell
lines enable direct genetic alteration of
mice in a pure genetic background.
Using a defined media supplement,
knockout serum replacement (KSR) with
knockout DMEM (KSR–KDMEM), the
investigators established ES cell lines
from blastocysts of C57BL/6J mice. One
specific cell line, HGTC–8 was found to
be karyotypically stable and germline
competent, both prior to manipulation
and after gene targeting. These cell lines
transfected more efficiently, and
exhibited increased efficiencies of cell
cloning and chimera generation, when
maintained in KSR–KDMEM.
Applications:
• Generation of knockout mice
without the need to backcross.
• Generation of mice via targeted
mutations.
Inventors: Jun Cheng, Lisa GarrettBeal, and Pamela L. Schwartzberg
(NHGRI).
Publication: J Cheng, A Dutra, A
Takesono, L Garrett-Beal, PL
Schwartzberg. Improved generation of
C57BL/6J mouse embryonic stem cells
in a defined serum-free media. Genesis.
2004 June; 39(2):100–104.
Patent Status: HHS Reference No. E–
038–2009/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
licensing under a Biological Materials
License Agreement.
Licensing Contact: Suryanarayana
(Sury) Vepa, Ph.D., J.D.; 301–435–5020;
vepas@mail.nih.gov.
Identification of Renal Cell Carcinoma
Biomarkers
Description of Technology: This
invention describes the identification of
potential renal cancer biomarkers which
could be utilized in the development of
a renal cancer diagnostics. The
invention identified cancer protein
biomarkers from clinically relevant
samples including peripheral blood and
E:\FR\FM\20MYN1.SGM
20MYN1
Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices
fresh frozen tissues. Vast availability of
fresh frozen tissues and peripheral
blood specimens that are easily obtained
could lead to clinical tests amenable to
therapeutic, prognostic and even early
screening tests for renal cell carcinoma
and other malignancies.
Applications: Renal cell carcinoma
diagnostics, therapeutics and
prognostics.
Market:
• Cancer is the second leading cause
of death in the U.S.A. There is an acute
need for cancer biomarkers that can be
detected from clinically relevant
samples and used for early diagnosis,
therapeutic follow-up and prognosis of
malignant diseases.
• The incidence of renal cell cancer
has been rising steadily. Renal Cell
Carcinoma is the most common type of
kidney cancer, and the most common
type in adults, responsible for
approximately 80% of cases.
Inventors: Josip Blonder et al. (NCI).
Patent Status: PCT Application No.
PCT/US2009/037855 filed 20 Mar 2009
(HHS Reference No. E–317–2008/0–
PCT–01)
Licensing Status: Available for
licensing.
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Laboratory of Proteomics and Analytical
Technologies is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize diagnostic, therapeutic
and prognostic cancer biomarkers from
clinical specimens. Please contact John
D. Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: May 13, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–11705 Filed 5–19–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary
and Alternative Medicine
Announcement of Workshop on the
Non-Pharmacological Management of
Back Pain
ACTION:
SUMMARY: The National Center for
Complementary and Alternative
Medicine (NCCAM) invites the research
community to participate in an online
Workshop on Non-Pharmacological
Management of Back Pain. The purpose
of this workshop is to identify and
explore a range of important and timely
clinical research questions related to
non-pharmacological interventions to
treat back pain. This information will
help inform future research directions
for NIH and the biomedical scientific
field. This workshop will be split into
three sessions that will feature
presentations and discussions focusing
on the current understanding and
complexity of chronic back pain,
promising questions associated with
testable hypotheses, and the relevant
outcome measures.
The Workshop will take place on May
27, 2009. Those interested in CAM
research are particularly encouraged to
view and participate.
Background: The National Center for
Complementary and Alternative
Medicine (NCCAM) was established in
1999 with the mission of exploring
complementary and alternative healing
practices in the context of rigorous
science, training CAM researchers, and
disseminating authoritative information
to the public and professionals. NCCAM
funds research grants that explore the
science of CAM. For more information,
see https://nccam.nih.gov/grants/
whatnccamfunds/.
Participating: The Workshop will be
broadcast on the Internet and archived
on https://www.videocast.nih.gov/.
Viewers may submit questions for the
presenters and panelists by e-mailing
nccambkpnwkshp@mail.nih.gov with
questions or comments. For more
information about what will be covered
at the workshop, see https://
nccam.nih.gov/news/events/.
FOR FURTHER INFORMATION CONTACT: To
request more information, visit the
NCCAM Web site at https://
nccam.nih.gov/news/events/, call 301–
594–3391 (Edward Culhane) or e-mail at
culhanee@mail.nih.gov.
Dated: May 12, 2009.
Richard Nahin,
Senior Advisor for Scientific Coordination
and Outreach, National Center for
Complementary and Alternative Medicine,
National Institutes of Health.
[FR Doc. E9–11679 Filed 5–19–09; 8:45 am]
BILLING CODE 4140–01–P
Notice.
VerDate Nov<24>2008
15:27 May 19, 2009
Jkt 217001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
23731
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Gastroenterology and Urology Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Gastroenterology
and Urology Devices Panel of the
Medical Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on Wednesday, June 10, 2009, from
8 a.m. to 5 p.m.
Location: Holiday Inn, Ballroom, Two
Montgomery Village Ave., Gaithersburg,
MD.
Contact Person: Megan Mickal, Center
for Devices and Radiological Health
(HFZ–470), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 240–276–4151, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code
3014512523. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The committee will discuss
and make recommendations regarding
general issues related to the use of
ultrafiltration devices in the treatment
of extracellular body fluid overload in
patients experiencing heart failure.
Specifically, the committee will address
the use of these devices in patients
experiencing heart failure in the
following terms: Identifying the most
appropriate heart failure patients for
whom these treatments should be
indicated, determining where these
treatments fit within the spectrum of
treatment options, and defining what
level of clinical evidence is necessary to
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 74, Number 96 (Wednesday, May 20, 2009)]
[Notices]
[Pages 23729-23731]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11705]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Antibody and Immunotoxin Treatments for Mesothelin-Expressing Cancers
Description of Technology: Mesothelin is a cell surface protein
that is highly expressed in aggressive cancers such as malignant
mesothelioma, ovarian cancer and pancreatic cancer. As a result,
mesothelin is an excellent candidate for tumor targeted
immunotherapeutics. However, the antibodies against mesothelin that are
available for clinical trials are of murine origin. These antibodies
have the potential to elicit immune responses in patients, which may
adversely affect the ability to provide patients with repeated doses.
Thus, the clinical application of the antibodies may be limited.
In order to address the issue of immunogenicity in patients, NIH
inventors have generated anti-mesothelin antibody variable fragments
(Fv) of human origin. These antibody fragments (HN1 and HN2) have the
ability to efficiently recognize mesothelin on the surface of numerous
cancer cells. As a result, these antibody fragments represent an
attractive therapeutic alternative to the murine anti-mesothelin
antibodies currently being tested in clinical trials.
Application:
Use as an antibody therapeutic for mesotheliomas,
pancreatic tumors and ovarian tumors.
Use in an immunotoxin therapeutic for mesotheliomas,
pancreatic tumors and ovarian tumors.
Diagnostic for the detection of mesothelin positive
tumors.
Research agent for the detection of mesothelin.
Advantages:
Fully human antibody reduces potential immunogenicity,
thereby allowing repeated dosing.
Antibody specificity improves the therapeutic efficacy of
the agent.
Development Status: Preclinical stage of development with some pre-
clinical data available.
Inventors: Mitchell Ho et al. (NCI).
Patent Status: U.S. Provisional Application No. 61/162,778, filed
24 Mar 2009 (HHS Reference E-091-2009/0-US-01)
Related Technologies/Publications:
U.S. Patent 6,083,502 entitled ``Mesothelium Antigen and
Methods and Kits For Targeting It.''
PCT Application PCT/US97/0224 entitled ``Mesothelium
Antigen and Methods and Kits For Targeting It.''
U.S. Patent 6,809,184 entitled ``Antibodies, Including Fv
Molecules, and Immunoconjugates Having High Binding Affinity for
Mesothelin and Methods for Their Use.''
PCT Application PCT/US98/25270 entitled ``Antibodies,
Including Fv Molecules, and Immunoconjugates Having High Binding
Affinity for Mesothelin and Methods for Their Use.''
U.S. Patent 7,081,518 entitled ``Anti-mesothelin
antibodies having high binding affinity.''
PCT Application PCT/US00/14829 entitled ``Immunoconjugates
Having High Binding Affinity Improvement of scFVsr Ab's with Higher
Affinity for Mesothelin.''
Licensing Status: Available for licensing.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Laboratory of Molecular Biology is seeking statements of capability or
interest from parties interested in collaborative research to further
[[Page 23730]]
develop, evaluate, or commercialize antibody-based treatments of
mesothelin-expressing cancers. Please contact John D. Hewes, Ph.D. at
301-435-3121 or hewesj@mail.nih.gov for more information.
Simple Biosensors Based on Electrical Percolation Biological
Semiconductors
Description of Technology: The invention offered for licensing is
in the field of biosensors with application in diagnostics and in
regulation of implantable biomedical devices. More specifically, it is
related to biological semiconductors based on the electrical
percolation of single-walled carbon nanotubes (SWNTs). The nanotubes
are embedded with biological ligands (e.g., antibodies). The electrical
resistance of a semiconducting SWNT is found to dramatically increase
upon the actuation by a specific antigen. Measurement of the change in
resistance correlates with the concentration of the specific antigen
and thus provides for quantitative determination and diagnostics of
biological samples. The simple printing fabrication of electrical
percolation biological semiconductors (EPBSC) can facilitate assembly
of numerous types of gates (e.g., antibodies, DNA, etc.) and print many
of such gates on the same chip for the creation of biological CPUs for
various biomedical applications, including direct biodetection and
regulation of implantable biomedical devices.
Applications:
(a) Miniaturized biosensors for various biomedical applications,
including: (i) Direct biodetection of microbial pathogens and their
toxins ii) diagnostics and prognostics of human diseases (e.g., cancer,
cardiovascular, or other biomarkers) (iii) detection and analysis of
nucleic acids (e.g., DNA, RNA) (iv) detection and analysis of other
analytes (carbohydrates, fatty acids, organic or inorganic compounds).
--Point of Care (POC) diagnostics (e.g., Physician's office, home-use)
--Military applications (e.g., remote sensing of biowarfare agents)
(b) Monitor food safety and detection of environmental pollution.
(c) Regulation of implantable biomedical devices such as insulin
pumps or artificial hearts.
(d) New generation of personal detectors (e.g., food allergens,
cardiovascular event, etc.).
Advantages:
(a) The electrical percolation biological semiconductors (EPBSC)
are relatively simple to assemble, and do not require specialized
fabrication facilities or experience which may broaden the use of EPBSC
in a similar way that PDMS (Polydimethylsiloxane) technology has
broadened the use of lab-on-a-chip.
(b) Many EPBSC can be fabricated into the same chip enabling
simultaneous detection of many analytes.
(c) Electronic based EPBS detection enable simple digital signal
amplification and analysis.
(d) EPBSC can be relatively stable with respect to retention of
biological viability and thus can be stored for a long period of time
before use.
(e) EPBSC enable device miniaturization.
(f) EPBSC are relatively simple to use and may not require special
equipment or a skilled operator. Thus, these biosensors can be utilized
in a Physician Office setting, for military applications and for
possibly remote sensing for detections of biowarfare materials.
(g) EPBSC devices will offer speed of detection, ease of use, and
it will be inexpensive to make.
Development Status: Proof of concept was demonstrated. For example,
using anti-Staphylococcal Enterotoxin B (SEB) IgG antibodies as a gate,
and the SEB antigen as an actuator, the inventors could detect as
little as 0.1 ng/mL of SEB.
Market: According to market research reports from 2003-2004 the
global market for biosensors was projected to grow from approximately
$7.0 billion in 2004 to approximately $9.5 billion in 2009, an average
annual growth of about 7.0%. Ninety-nine percent (99%) of the
biosensor's market is dominated by biomedical and life sciences, while
only one percent (1.0%) with applications in environmental monitoring.
Because of the unique advantages offered by this technology (i.e.,
diversity of applications, simplicity of use and low cost), there is a
good probability that if technically successful it will become
commercially successful and financially rewarding.
Inventors: Avraham Rasooly (NCI) et al.
Patent Status: U.S. Provisional Application No. 61/115,546 filed 18
Nov 2008, entitled ``Electrical Percolation Biomedical Semiconductors''
(HHS Reference No. E-040-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, Ph.D., MBA; 301-435-4616;
UR7a@nih.gov; Michael Shmilovich, JD; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Cancer Diagnostic Program, and the Food and Drug Administration, the
Center for Devices and Radiological Health, Office of Science and
Engineering Laboratories, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize Electrical Percolation Biological
Semiconductors for biodetection. Please contact John D. Hewes, Ph.D. at
301-435-3121 or hewesj@mail.nih.gov for more information.
C57BL/6J Embryonic Stem Cell Lines Generated Using Serum-Free Media
Description of Technology: NIH investigators have generated
Embryonic Stem (ES) cell clones from C57BL/6J mice in a defined medium.
These cell lines enable direct genetic alteration of mice in a pure
genetic background.
Using a defined media supplement, knockout serum replacement (KSR)
with knockout DMEM (KSR-KDMEM), the investigators established ES cell
lines from blastocysts of C57BL/6J mice. One specific cell line, HGTC-8
was found to be karyotypically stable and germline competent, both
prior to manipulation and after gene targeting. These cell lines
transfected more efficiently, and exhibited increased efficiencies of
cell cloning and chimera generation, when maintained in KSR-KDMEM.
Applications:
Generation of knockout mice without the need to backcross.
Generation of mice via targeted mutations.
Inventors: Jun Cheng, Lisa Garrett-Beal, and Pamela L. Schwartzberg
(NHGRI).
Publication: J Cheng, A Dutra, A Takesono, L Garrett-Beal, PL
Schwartzberg. Improved generation of C57BL/6J mouse embryonic stem
cells in a defined serum-free media. Genesis. 2004 June; 39(2):100-104.
Patent Status: HHS Reference No. E-038-2009/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing under a Biological
Materials License Agreement.
Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301-435-
5020; vepas@mail.nih.gov.
Identification of Renal Cell Carcinoma Biomarkers
Description of Technology: This invention describes the
identification of potential renal cancer biomarkers which could be
utilized in the development of a renal cancer diagnostics. The
invention identified cancer protein biomarkers from clinically relevant
samples including peripheral blood and
[[Page 23731]]
fresh frozen tissues. Vast availability of fresh frozen tissues and
peripheral blood specimens that are easily obtained could lead to
clinical tests amenable to therapeutic, prognostic and even early
screening tests for renal cell carcinoma and other malignancies.
Applications: Renal cell carcinoma diagnostics, therapeutics and
prognostics.
Market:
Cancer is the second leading cause of death in the U.S.A.
There is an acute need for cancer biomarkers that can be detected from
clinically relevant samples and used for early diagnosis, therapeutic
follow-up and prognosis of malignant diseases.
The incidence of renal cell cancer has been rising
steadily. Renal Cell Carcinoma is the most common type of kidney
cancer, and the most common type in adults, responsible for
approximately 80% of cases.
Inventors: Josip Blonder et al. (NCI).
Patent Status: PCT Application No. PCT/US2009/037855 filed 20 Mar
2009 (HHS Reference No. E-317-2008/0-PCT-01)
Licensing Status: Available for licensing.
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Laboratory of Proteomics and Analytical Technologies is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
diagnostic, therapeutic and prognostic cancer biomarkers from clinical
specimens. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: May 13, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E9-11705 Filed 5-19-09; 8:45 am]
BILLING CODE 4140-01-P
